Manager TitleAgeSince
Chief Executive Officer 53 -
Director of Finance/CFO 67 -
General Counsel 65 -
Date Insider Type Main position Quantity % Market Cap.
16/04/21 Issuer sale

Director

80,000 0.1718%
16/04/21 Issuer sale

Director

72,500 0.1557%
16/04/21 Issuer sale

Director

80,000 0.1718%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.16% - - 174.05Cr
+1.23%+0.35%+51.62%+87.98% 5.59TCr
+3.94%+10.16%+67.69%+72.98% 5.67TCr
+0.25%+0.55%-19.67%-15.22% 2.33TCr
+0.72%-0.05%+3.84%+409.54% 2.33TCr
-0.36%+5.73%+30.99%-3.58% 2.05TCr
-0.70%+1.02%+25.66%-29.92% 1.78TCr
-1.44%+5.67%+32.54%+544.11% 1.59TCr
-2.54%-8.73%+164.11%+289.45% 1.46TCr
+1.22%-0.05%+22.58%+182.63% 1.4TCr
Average +0.24%+1.26%+42.15%+170.89% 2.69TCr
Weighted average by Cap. +1.03%+3.18%+44.14%+136.67%
Logo Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company's pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
Employees
51
  1. Stock Market
  2. Stocks
  3. FPRX Stock